Literature DB >> 17664028

Childhood and adolescent depression: why do children and adults respond differently to antidepressant drugs?

David B Bylund1, Abbey L Reed.   

Abstract

Childhood and adolescent depression is an increasingly problematic diagnosis for young people due to a lack of effective treatments for this age group. The symptoms of adult depression can be treated effectively with multiple classes of antidepressant drugs which have been developed over the years using animal and human studies. But many of the antidepressants used to treat adult depression cannot be used for pediatric depression because of a lack of efficacy and/or side effects. The reason that children and adolescents respond differently to antidepressant treatment than adults is poorly understood. In order to better understand the etiology of pediatric depression and treatments that are effective for this age group, the differences between adults, children and adolescents needed to be elucidated. Much of the understanding of adult depression has come from studies using adult animals, therefore studies using juvenile animals would likely help us to better understand childhood and adolescent depression. Recent studies have shown both neurochemical and behavioral differences between adult and juvenile animals after antidepressant treatment. Juvenile animals have differences compared to adult animals in the maturation of the serotonergic and noradrenergic systems, and in dose of antidepressant drug needed to achieve similar brain levels. Differences after administration of antidepressant drug have also been reported for adrenergic receptor regulation, a physiologic hypothermic response, as well as behavioral differences in two animal models of depression. The differences between adults and juveniles not only in the human response to antidepressants but also with animals studies warrant a specific distinction between the study of pediatric and adult depression and the manner in which new treatments are pursued.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17664028      PMCID: PMC2694752          DOI: 10.1016/j.neuint.2007.06.025

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  38 in total

Review 1.  Major depressive disorder.

Authors:  M Fava; K S Kendler
Journal:  Neuron       Date:  2000-11       Impact factor: 17.173

Review 2.  Models and responses in depression and aggression.

Authors:  J P Kelly; B E Leonard
Journal:  Biochem Soc Trans       Date:  1998-02       Impact factor: 5.407

Review 3.  Stress, norepinephrine and depression.

Authors:  B E Leonard
Journal:  J Psychiatry Neurosci       Date:  2001       Impact factor: 6.186

Review 4.  Assessing antidepressant activity in rodents: recent developments and future needs.

Authors:  John F Cryan; Athina Markou; Irwin Lucki
Journal:  Trends Pharmacol Sci       Date:  2002-05       Impact factor: 14.819

5.  Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment.

Authors:  John F Cryan; Michelle E Page; Irwin Lucki
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

Review 6.  Mood disorders in children and adolescents: an epidemiologic perspective.

Authors:  R C Kessler; S Avenevoli; K Ries Merikangas
Journal:  Biol Psychiatry       Date:  2001-06-15       Impact factor: 13.382

Review 7.  Treatment options in the management of adolescent depression.

Authors:  E B Weller; R A Weller
Journal:  J Affect Disord       Date:  2000-12       Impact factor: 4.839

8.  Chronic treatment with desipramine facilitates its effect on extracellular noradrenaline in the rat hippocampus: studies on the role of presynaptic alpha2-adrenoceptors.

Authors:  G Sacchetti; M Bernini; M Gobbi; S Parini; L Pirona; T Mennini; R Samanin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-01       Impact factor: 3.000

Review 9.  Preclinical models: status of basic research in depression.

Authors:  Eric J Nestler; Elizabeth Gould; Husseini Manji; Maja Buncan; Ronald S Duman; Howard K Greshenfeld; Ren Hen; Susan Koester; Israel Lederhendler; Michael Meaney; Trevor Robbins; Lois Winsky; Steve Zalcman
Journal:  Biol Psychiatry       Date:  2002-09-15       Impact factor: 13.382

10.  Juvenile rats in the forced-swim test model the human response to antidepressant treatment for pediatric depression.

Authors:  Abbey L Reed; H Kevin Happe; Frederick Petty; David B Bylund
Journal:  Psychopharmacology (Berl)       Date:  2008-01-08       Impact factor: 4.530

View more
  38 in total

1.  Escitalopram in the treatment of major depressive disorder in adolescent patients. Profile report.

Authors:  Lily P H Yang; Lesley J Scott
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

2.  Iatrogenic comorbidity in childhood and adolescence: new insights from the use of antidepressant drugs.

Authors:  Emanuela Offidani; Giovanni A Fava; Nicoletta Sonino
Journal:  CNS Drugs       Date:  2014-09       Impact factor: 5.749

3.  Abnormal protein and mRNA expression of inflammatory cytokines in the prefrontal cortex of depressed individuals who died by suicide.

Authors:  Ghanshyam N Pandey; Hooriyah S Rizavi; Hui Zhang; Runa Bhaumik; Xinguo Ren
Journal:  J Psychiatry Neurosci       Date:  2018-06-11       Impact factor: 6.186

4.  Brain-derived neurotrophic factor (BDNF) Val66Met and adulthood chronic stress interact to affect depressive symptoms.

Authors:  Rong Jiang; Beverly H Brummett; Michael A Babyak; Ilene C Siegler; Redford B Williams
Journal:  J Psychiatr Res       Date:  2012-11-08       Impact factor: 4.791

Review 5.  Bright light therapy in the treatment of childhood and adolescence depression, antepartum depression, and eating disorders.

Authors:  Krzysztof Krysta; Marek Krzystanek; Małgorzata Janas-Kozik; Irena Krupka-Matuszczyk
Journal:  J Neural Transm (Vienna)       Date:  2012-07-19       Impact factor: 3.575

Review 6.  Escitalopram: in the treatment of major depressive disorder in adolescent patients.

Authors:  Lily P H Yang; Lesley J Scott
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

Review 7.  Understanding developmental pharmacodynamics: importance for drug development and clinical practice.

Authors:  Hussain Mulla
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

Review 8.  Ontogeny and regulation of the serotonin transporter: providing insights into human disorders.

Authors:  Lynette C Daws; Georgianna G Gould
Journal:  Pharmacol Ther       Date:  2011-04-05       Impact factor: 12.310

9.  Antidepressant-like effects and basal immobility depend on age and serotonin transporter genotype.

Authors:  Wouter Koek; Lynette C Daws; Nathan C Mitchell
Journal:  Genes Brain Behav       Date:  2015-09       Impact factor: 3.449

10.  Engrailed-2 (En2) deletion produces multiple neurodevelopmental defects in monoamine systems, forebrain structures and neurogenesis and behavior.

Authors:  Matthieu Genestine; Lulu Lin; Madel Durens; Yan Yan; Yiqin Jiang; Smrithi Prem; Kunal Bailoor; Brian Kelly; Patricia K Sonsalla; Paul G Matteson; Jill Silverman; Jacqueline N Crawley; James H Millonig; Emanuel DiCicco-Bloom
Journal:  Hum Mol Genet       Date:  2015-07-28       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.